Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K C Lasseter

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Journal of Clinical Pharmacology|November 1, 1984
Oxaprozin dose proportionalityS T Chiang, K C Lasseter, E R Fluck, et al.
Journal of Clinical Pharmacology|March 22, 2005
FTY720 pharmacokinetics in mild to moderate hepatic impairmentJ M Kovarik, R L Schmouder, D Serra, et al.
The American Journal of Cardiology|March 12, 1999
Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study InvestigatorsT P Bell, V DeQuattro, K C Lasseter, et al.
Clinical Pharmacology and Therapeutics|January 1, 1994
Pharmacodynamics of MK-0963, a new 5 alpha-reductase inhibitor: effects on serum androgen concentrationsJ I Schwartz, O L Laskin, C A Meeter, et al.
Journal of Cardiovascular Pharmacology|January 1, 1984
Steady-state pharmacokinetics of nitrendipine in hepatic insufficiencyK C Lasseter, E C Shamblen, A A Murdoch, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1990
Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteersG J Gormley, E Stoner, R S Rittmaster, et al.
European Journal of Clinical Pharmacology|May 9, 2007
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptinY-L He, R Sabo, J Campestrini, et al.
Neurology|November 1, 1989
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studiesK C Yeh, T F August, D F Bush, et al.
The American Review of Respiratory Disease|August 1, 1986
Comparative absorption of inhaled and intramuscularly administered atropineL I Harrison, R C Smallridge, K C Lasseter, et al.
Biopharmaceutics & Drug Disposition|July 1, 1994
The bioavailability and nonlinear pharmacokinetics of MK-679 in humansH Cheng, J I Schwartz, C Lin, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Journal of Clinical Pharmacology|November 1, 1984
Oxaprozin dose proportionalityS T Chiang, K C Lasseter, E R Fluck, et al.
Journal of Clinical Pharmacology|March 22, 2005
FTY720 pharmacokinetics in mild to moderate hepatic impairmentJ M Kovarik, R L Schmouder, D Serra, et al.
The American Journal of Cardiology|March 12, 1999
Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study InvestigatorsT P Bell, V DeQuattro, K C Lasseter, et al.
Clinical Pharmacology and Therapeutics|January 1, 1994
Pharmacodynamics of MK-0963, a new 5 alpha-reductase inhibitor: effects on serum androgen concentrationsJ I Schwartz, O L Laskin, C A Meeter, et al.
Journal of Cardiovascular Pharmacology|January 1, 1984
Steady-state pharmacokinetics of nitrendipine in hepatic insufficiencyK C Lasseter, E C Shamblen, A A Murdoch, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1990
Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteersG J Gormley, E Stoner, R S Rittmaster, et al.
European Journal of Clinical Pharmacology|May 9, 2007
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptinY-L He, R Sabo, J Campestrini, et al.
Neurology|November 1, 1989
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studiesK C Yeh, T F August, D F Bush, et al.
The American Review of Respiratory Disease|August 1, 1986
Comparative absorption of inhaled and intramuscularly administered atropineL I Harrison, R C Smallridge, K C Lasseter, et al.
Biopharmaceutics & Drug Disposition|July 1, 1994
The bioavailability and nonlinear pharmacokinetics of MK-679 in humansH Cheng, J I Schwartz, C Lin, et al.
Pageof 6